Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/23/2025

Vaccination Recommendations for Patients with Rheumatic Heart Disease

Core Vaccinations

  • The American College of Rheumatology recommends that patients with rheumatic heart disease receive influenza, pneumococcal, and recombinant varicella-zoster virus vaccinations, with influenza vaccination being strongly recommended annually regardless of immunosuppressive therapy 1, 2, 3
  • High-dose or adjuvanted influenza vaccination is conditionally recommended over regular-dose influenza for patients with rheumatic diseases who are ≥65 years or >18 years and <65 years taking immunosuppressive medications 1, 3
  • Influenza vaccination should be administered annually and on schedule, even for patients on immunosuppressive therapies including rituximab 4, 5
  • Pneumococcal vaccination is strongly recommended for patients with rheumatic diseases who are <65 years and taking immunosuppressive medications 1, 2
  • Recombinant VZV vaccine is strongly recommended for patients with rheumatic diseases >18 years who are taking immunosuppressive medication 1, 6

Medication Considerations

  • The American College of Rheumatology recommends considering holding methotrexate for 2 weeks after influenza vaccination if disease activity allows 5
  • For patients on rituximab, administer influenza vaccination on schedule regardless of rituximab timing, but delay any subsequent rituximab dosing for at least 2 weeks after vaccination if disease activity allows 4, 5
  • For patients on prednisone ≥20 mg daily, administer influenza vaccination, but consider deferring other non-live vaccinations until glucocorticoids are tapered to <20 mg daily 4, 7

Additional Considerations

  • The American College of Cardiology recommends secondary prevention of rheumatic fever with antibiotic prophylaxis in all patients with rheumatic heart disease 8
  • For patients with rheumatic heart disease and residual valvular disease, prophylaxis should continue for at least 10 years or until age 40 (whichever is longer) 8
  • Non-live vaccinations are conditionally recommended regardless of disease activity 7
  • Multiple vaccinations can be administered on the same day rather than on different days 9

REFERENCES